Last reviewed · How we verify

NCT04019314

Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)

Completed NA Last updated 23 August 2022
What this trial tests

NA trial testing Blood Collection in Heart Failure in 20 participants. Completed in 6 October 2021.

Timeline
11 June 2019
Primary endpoint
6 October 2021
6 October 2021

Quick facts

Lead sponsorMayo Clinic
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment20
Start date11 June 2019
Primary completion6 October 2021
Estimated completion6 October 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Heart Failure or Volume Overload. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Researchers are observing the values of proEnkephalin (PENK) via a blood draw in hospitalized patients that are volume overloaded requiring diuresis. If changes in PENK are found, physicians may predict values of change in kidney function during treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood Collection

Trials testing the same drug.

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04019314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing